<!-- Content: Uterine LMS -->
<div class="content-container">
  <!-- Featured Publication -->
  <section id="featured-publication" class="section">
    <h2 class="section-title gradient-text">Featured Publication</h2>
    <div class="card pub-card">
      <div class="pub-media">
        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11578816" target="_blank" rel="noopener">
          <img src="https://leiomyosarcoma.info/wp-content/uploads/2021/03/Cancers.png" alt="Featured Research" />
        </a>
      </div>
      <div class="pub-body">
        <h3 class="pub-title">
          <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11578816" target="_blank" rel="noopener">
            Uterine SM Tumors of Uncertain Malignant Potential — 13‑year retrospective study (2024)
          </a>
        </h3>
        <p class="muted">Comprehensive retrospective study informing diagnosis and management for uterine smooth muscle tumors of uncertain malignant potential.</p>
      </div>
    </div>
  </section>

  <!-- Expert Video & Center Spotlight -->
  <section id="expert-video" class="section">
    <h2 class="section-title gradient-text">Expert Video: Sarcoma Care Insights</h2>
    <div class="card">
      <h3 class="card-title">Uterine Sarcoma Care — Key Considerations</h3>
      <div class="video-wrapper" style="position:relative;padding-bottom:56.25%;height:0;overflow:hidden;border-radius:12px;box-shadow:0 6px 18px rgba(0,0,0,0.08);">
        <iframe
          src="https://www.youtube.com/embed/KzPj_xrz334"
          title="Uterine Sarcoma Care"
          frameborder="0"
          allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share"
          allowfullscreen
          style="position:absolute;top:0;left:0;width:100%;height:100%;border:0;border-radius:12px;"
        ></iframe>
      </div>
      <p class="muted" style="margin-top:0.75rem;">
        Multidisciplinary sarcoma programs bring together surgical, medical, and radiation oncology expertise, with access to advanced imaging and clinical trials. For an overview of comprehensive sarcoma services — including evaluation, treatment planning, and second opinions — see the
        <a class="resource-link" href="https://www.uclahealth.org/cancer/cancer-services/sarcoma" target="_blank" rel="noopener">UCLA Health Sarcoma Center</a>.
      </p>
    </div>
  </section>

  <!-- Recent Literature -->
  <section id="recent-literature" class="section">
    <h2 class="section-title gradient-text">Recent Literature: IJGC Review (2025)</h2>
    <div class="literature-card">
      <h3 class="literature-title">Uterine Leiomyosarcoma — International Panel Review</h3>
      <p class="literature-meta">International Journal of Gynecological Cancer • September 2025 • Review</p>
      <ul class="lit-bullets">
        <li><strong>Biology</strong>: Multifactorial pathogenesis with complex cytogenetic/molecular alterations (e.g., TP53, RB1; chromothripsis patterns).</li>
        <li><strong>Diagnosis</strong>: Preoperative distinction from leiomyoma remains difficult; MRI/CT assist but no single definitive test. Avoid morcellation when malignancy is suspected.</li>
        <li><strong>Primary treatment</strong>: Stage I—en bloc total hysterectomy ± BSO; routine lymphadenectomy not indicated without bulky nodes. Centralized, multidisciplinary care is emphasized.</li>
        <li><strong>Stage II–IV/recurrent</strong>: Aim for complete resection when feasible; adjuvant chemo/RT evidence is mixed. Systemic options are doxorubicin‑based; consider RT and multimodal strategies.</li>
        <li><strong>Follow‑up</strong>: Regular clinical and imaging surveillance due to high early recurrence risk; patterns often distant (lung/liver).</li>
        <li><strong>Guidelines & variability</strong>: ESGO/EURACAN/GCIG recommendations summarized; notable international practice differences persist.</li>
      </ul>
      <a class="lit-link" href="https://www.international-journal-of-gynecological-cancer.com/article/S1048-891X(25)01112-0/fulltext" target="_blank" rel="noopener">Read the full IJGC 2025 review</a>
    </div>
  </section>

  <!-- Genomic Risk Stratification -->
  <section id="genomic-risk" class="section">
    <h2 class="section-title gradient-text">Genomic Risk Stratification in uLMS</h2>
    <div class="card">
      <h3 class="card-title">Developing Novel Genomic Risk Stratification Models</h3>
      <p>Dermawan JK et al. propose a clinically applicable genomic risk model for LMS, addressing heterogeneity and current gaps in risk tools.</p>
      <ul class="resource-list">
        <li><a class="resource-link" href="https://aacrjournals.org/clincancerres/article-abstract/30/10/2260/745180/Developing-Novel-Genomic-Risk-Stratification?redirectedFrom=fulltext" target="_blank" rel="noopener">Clinical Cancer Research (2024) — Abstract</a></li>
        <li><a class="resource-link" href="https://doi.org/10.1158/1078-0432.CCR-24-0148" target="_blank" rel="noopener">DOI: 10.1158/1078-0432.CCR-24-0148</a></li>
      </ul>
    </div>
    <div class="card">
      <h3 class="card-title">Transcriptome profiling: leiomyoma-like program indicates better survival</h3>
      <p>Multi-cohort transcriptomic profiling identifies a subset of uterine LMS with a leiomyoma-like expression pattern associated with more favorable outcomes, suggesting utility for prognostic stratification and biological insight.</p>
      <ul class="resource-list">
        <li><a class="resource-link" href="https://www.nature.com/articles/s44276-025-00190-x" target="_blank" rel="noopener">Nature (2025) — Article</a></li>
      </ul>
    </div>
  </section>

  <!-- Targeted Therapy Review -->
  <section id="targeted-therapy" class="section">
    <h2 class="section-title gradient-text">Targeted Therapy — MD Anderson Review</h2>
    <div class="card">
      <h3 class="card-title">The Future of Targeted Therapy for Leiomyosarcoma</h3>
      <p>Review of DNA damage response, macrophage‑rich microenvironment, PI3K/mTOR, epigenetic regulators, and telomere biology in LMS.</p>
      <ul class="resource-list">
        <li><a class="resource-link" href="https://www.mdpi.com/2072-6694/16/5/938" target="_blank" rel="noopener">Cancers (2024): 10.3390/cancers16050938</a></li>
      </ul>
    </div>
  </section>

  <!-- Hormone Therapy (Aromatase Inhibitors) -->
  <section id="hormone-therapy" class="section">
    <h2 class="section-title gradient-text">Hormone Therapy: Aromatase Inhibitors</h2>
    <div class="card">
      <h3 class="card-title">Letrozole and AI use in uLMS</h3>
      <p><strong>Q:</strong> Studies on Letrozole — suitability for stage I/II vs advanced (III/IV)?<br>
         <strong>A:</strong> Best studied in metastatic setting; benefit variable; some patients may benefit anecdotally.</p>
      <ul class="resource-list">
        <li><a class="resource-link" href="https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.28476" target="_blank" rel="noopener">DFCI publication (Cancer)</a></li>
        <li><a class="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/19932916/" target="_blank" rel="noopener">Treatment of advanced uLMS with aromatase inhibitors</a></li>
        <li><a class="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/24222211/" target="_blank" rel="noopener">Phase II Letrozole in ER/PR+ uLMS</a></li>
        <li><a class="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/25018868/" target="_blank" rel="noopener">Hormone‑positive uLMS with AIs</a></li>
      </ul>
    </div>
  </section>

  <!-- Research & Clinical Trials Links -->
  <section id="research-links" class="section">
    <h2 class="section-title gradient-text">Research & Clinical Trials</h2>
    <ul class="resource-list">
      <li><a class="resource-link" href="https://www.onclive.com/view/olaparib-temozolomide-shows-encouraging-efficacy-manageable-safety-in-uterine-leiomyosarcoma" target="_blank" rel="noopener">Temozolomide + Olaparib shows encouraging efficacy in uLMS</a></li>
      <li><a class="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/35660331/" target="_blank" rel="noopener">Adjuvant therapy utilization outcomes — Stage II/III uLMS</a></li>
      <li><a class="resource-link" href="https://www.sciencedirect.com/science/article/pii/S104366182300049X?via%3Dihub" target="_blank" rel="noopener">Targeting UCP2 in uLMS</a></li>
      <li><a class="resource-link" href="https://www.mdpi.com/2075-4418/13/3/543" target="_blank" rel="noopener">Overlap of suspicious features on ultrasound — single center</a></li>
      <li><a class="resource-link" href="https://leiomyosarcoma.info/wp-content/uploads/2022/02/Uterine-LMS-Staging-Chart-and-comprehensive-study.docx.pdf" target="_blank" rel="noopener">Uterine LMS Staging Chart — comprehensive study</a></li>
    </ul>
  </section>

  <!-- Full Research Archive (Verbatim) -->
  <section id="full-research-archive" class="section">
    <h2 class="section-title gradient-text">Full Research Archive (Verbatim)</h2>
    <p class="muted">Imported exactly as provided to ensure every original item appears. Collapsed by default for readability.</p>
    <details class="raw-archive">
      <summary>View full archive</summary>
      <div class="raw-archive-inner">
        <!-- BEGIN VERBATIM IMPORT -->
        <div class="elementor-widget-wrap">
          <div class="elementor-element elementor-element-58e1d0aa elementor-widget elementor-widget-text-editor" data-id="58e1d0aa" data-element_type="widget" data-widget_type="text-editor.default">
            <div class="elementor-widget-container">
              <div class="elementor-text-editor elementor-clearfix">
                <!-- User-provided HTML starts -->
                <div><div><div dir="ltr" data-setdir="false"><div><div>&nbsp;</div><div><div dir="ltr" data-setdir="false"><h1><span style="font-size: medium;">Uterine smooth muscle tumors of uncertain malignant potential: a 13-year retrospective study (7 November 2024)</span></h1></div><div dir="ltr" data-setdir="false"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11578816" target="_blank" rel="noopener">https://pmc.ncbi.nlm.nih.gov/articles/PMC11578816</a></div></div><div>&nbsp;</div><div><span style="font-size: large;"><strong>Recent Research Articles Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma</strong><br></span></div><div>Dermawan JK, Chiang S, Singer S, Jadeja B, Hensley ML, Tap WD, Movva S, Maki RG, Antonescu CR. Purpose: Leiomyosarcomas (LMS) are clinically and molecularly heterogeneous tumors. Despite genomic studies, current LMS risk stratification is not informed by molecular alterations. We propose a clinically applicable genomic risk stratification model. Clinical Cancer Research, 2024 Mar 15. Online ahead of print. PMID: 38488807. DOI: 10.1158/1078-0432.CCR-24-0148&nbsp;<wbr></div><div dir="ltr" data-setdir="false"><a class="" href="https://aacrjournals.org/clincancerres/article-abstract/30/10/2260/745180/Developing-Novel-Genomic-Risk-Stratification?redirectedFrom=fulltext" target="_blank" rel="noopener">https://aacrjournals.org/clincancerres/article-abstract/30/10/2260/745180/Developing-Novel-Genomic-Risk-Stratification?redirectedFrom=fulltext</a></div><div>&nbsp;</div></div><div>&nbsp;</div><div><strong><span style="font-size: large;">The Future of Targeted Therapy for Leiomyosarcoma New from MD Anderson:</span></strong></div><div>Denu RA, Dann AM, Keung EZ, Nakazawa MS, Nassif Haddid E. Abstract: Leiomyosarcoma (LMS) is an aggressive subtype of soft tissue sarcoma that arises from smooth muscle cells, most commonly in the uterus and retroperitoneum. LMS is a heterogeneous disease with diverse clinical and molecular characteristics that have yet to be fully understood. Molecular profiling has uncovered possible targets amenable to treatment, though this has yet to translate into approved targeted therapies in LMS. This review will explore historic and recent findings from molecular profiling, highlight promising avenues of current investigation, and suggest possible future strategies to move toward the goal of molecularly matched treatment of LMS. We focus on targeting the DNA damage response, the macrophage-rich micro-environment, the PI3K/mTOR pathway, epigenetic regulators, and telomere biology. Cancers, 2024 Feb. 26, DOI: 10.3390/cancers16050938.</div><p><a class="" href="https://www.mdpi.com/2072-6694/16/5/938" target="_blank" rel="noopener">https://www.mdpi.com/2072-6694/16/5/938</a></p></div><div>&nbsp;</div><h3>&nbsp;</h3><h3>&nbsp;</h3><h3>About Aromatase Inhibitors:</h3><p><img decoding="async" class="CToWUd" src="https://ci5.googleusercontent.com/proxy/T8QhihKXGd_12VsxVsDdGcoK1Fazz8zLTziWK8D1GIhfntWh_eH9CFowKf0cyN8kHlqq8whHZ9mMSEEWV1U3RSaos1vELHRg5-V9hQBEVND7K90UU_lcAYr6fHyy7rFsJScXqN0lfSt9osQuuCVJk2iI_t30eQ=s0-d-e1-ft#https://mcusercontent.com/7882c1010a69171493a3bed4b/images/6f4f5f3a-655c-4530-b6fc-7516a9a28dfd.jpg" width="88" height="88"></p><p><strong>Q:</strong>&nbsp; Studies on Letrozole – debate on whether it is best for Stage 1,2 Ulms instead of&nbsp;advanced states 3, 4:</p><p><strong>A: “&nbsp;</strong>Letrozole has been best studied (though small studies) in the metastatic setting. Here is a link to a publication from the DFCI group: <a href="https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.28476">https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.28476&nbsp;</a><br>It’s really not clear how much benefit these drugs have, but anecdotally patients can benefit.”</p><ul><li>&nbsp;Matt Hemming, MD, Dana Farber Cancer Institute / LMS International Research Roundtable &nbsp;&nbsp;Workgroup Leader for LMS cell lines / PDX model</li></ul><p>The primary literature is in metastatic disease ( stage 4) – the only trial which attempted to answer the question in early stage disease was closed due to poor accrual.<br>Some of the literature in the advanced setting is below.</p><ul><li>Suzanne George, Dana Farber Cancer Institute / LMS International Research Roundtable Member</li></ul>
                <!-- User-provided HTML continues ... (More content below in the next chunk if needed) -->
              </div>
            </div>
          </div>
        </div>
        <!-- Additional verbatim chunk -->
        <div class="elementor-widget-wrap">
          <div class="elementor-element elementor-widget elementor-widget-text-editor">
            <div class="elementor-widget-container">
              <div class="elementor-text-editor elementor-clearfix">
                <ul>
                  <li>Suzanne George, Dana Farber Cancer Institute / LMS International Research Roundtable Member</li>
                </ul>
                <h4>UTERINE LMS and Temolizomide / Olaparib treatment strategy</h4>
                <h4><strong>Dr. Matthew Ingham and Dr. Sam Bose present on Advanced uterine LMS – the Clinical Science Symposium at ASCO: </strong><a href="https://www.onclive.com/view/olaparib-temozolomide-shows-encouraging-efficacy-manageable-safety-in-uterine-leiomyosarcoma?fbclid=IwAR05Ks-v50HFqLBY6zgv" target="_blank" rel="noopener"><strong>https://www.onclive.com/view/olaparib-temozolomide-shows-encouraging-efficacy-manageable-safety-in-uterine-leiomyosarcoma</strong></a></h4>
                <p><strong>Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma</strong> — <a href="https://pubmed.ncbi.nlm.nih.gov/35660331/" target="_blank" rel="noopener">https://pubmed.ncbi.nlm.nih.gov/35660331/</a></p>

                <p><strong>Novel Therapeutic Strategies targeting UCP2 in uLMS:</strong><br>
                <a href="https://www.sciencedirect.com/science/article/pii/S104366182300049X?via%3Dihub" target="_blank" rel="noopener">https://www.sciencedirect.com/science/article/pii/S104366182300049X?via%3Dihub</a></p>

                <p><strong>Overlap of Suspicious and Non-suspicious features in the Ultrasound Evaluation of Leiomyosarcoma – a Single-Center Experience</strong><br>
                <a href="https://www.mdpi.com/2075-4418/13/3/543" target="_blank" rel="noopener">https://www.mdpi.com/2075-4418/13/3/543</a></p>

                <p><a style="color: #99cc00;" href="https://leiomyosarcoma.info/wp-content/uploads/2022/02/Uterine-LMS-Staging-Chart-and-comprehensive-study.docx.pdf">Uterine LMS Staging Chart and comprehensive study</a></p>

                <h3>Uterine LMS Research Rapid</h3>
                <ul>
                  <li>
                    <blockquote>
                      <div>Important Video presentation on Uterine LMS research progress updates provided by Dr. Matthew Ingham, Columbia University Medical Center, on uterine sarcomas at the American Society of Clinical Oncology (ASCO)</div>
                      <div><a href="https://www.vumedi.com/video/asco-2022-novel-therapeutics-in-the-treatment-of-uterine-sarcoma/?token=7f15b18e-df52-41f3-8c3b-e2ef7ff73686" target="_blank" rel="nofollow noopener noreferrer">ASCO 2022: Novel Therapeutics in the Treatment of Uterine Sarcoma</a> — link: <a href="https://bit.ly/3qqNM6d" target="_blank" rel="noopener">https://bit.ly/3qqNM6d</a></div>
                    </blockquote>
                  </li>
                  <li>
                    <blockquote>
                      <div>Dr. Ingham is an esteemed member of the NLMSF‑SPAGN International LMS Research Roundtable and on the Executive Committee of the NLMSF.</div>
                      <div>His presentation to the NLMSF Patient – Caregiver Advocacy Roundtable is here: <a href="https://youtu.be/mY2q7q5VOlA" target="_blank" rel="nofollow noopener noreferrer">https://youtu.be/mY2q7q5VOlA</a></div>
                      <div><u>Clinical Trial on Uterine LMS (last updated Aug 24, 2022):</u></div>
                      <div>A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma — PI: Mathew Ingham, MD — <a href="https://clinicaltrials.gov/ct2/show/NCT03880019" target="_blank" rel="nofollow noopener noreferrer">NCT03880019</a></div>
                      <div>Additionally, Dr. Gary Schwartz presented to the NLMSF Patient‑Caregiver Advocacy Roundtable:</div>
                      <div><strong>Dr. Gary Schwartz discussed the large clinical trial going into Phase III for uterine LMS clinical trial update:</strong> <a href="https://www.onclive.com/view/olaparib-temozolomide-shows-encouraging-efficacy-manageable-safety-in-uterine-leiomyosarcoma?fbclid=IwAR05Ks-v50HFqLBY6zgv" target="_blank" rel="nofollow noopener noreferrer">OncLive article</a></div>
                      <div>Recorded presentation: <a href="https://youtu.be/62gyn3nt6Z8" target="_blank" rel="nofollow noopener noreferrer">https://youtu.be/62gyn3nt6Z8</a></div>
                    </blockquote>
                  </li>
                  <li><a href="https://www.mdpi.com/1422-0067/23/17/9728/htm" target="_blank" rel="noopener">Molecular Insights in Uterine Leiomyosarcoma: A Systematic Review</a></li>
                  <li><a href="https://www.prnewswire.com/news-releases/preliminary-results-presented-at-asco-demonstrated-promising-clinical-efficacy-with-unesbulin-in-leiomyosarcoma-study-301560763.html" target="_blank" rel="noopener">New and promising drug – Unesbulin</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/35726279/" target="_blank" rel="noopener">Long‑Term Efficacy and Safety of Anlotinib for Advanced Sarcomas</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/35715148/" target="_blank" rel="noopener">Leiomyosarcoma: Current Clinical Management and Future Horizon</a></li>
                  <li><a href="https://aacrjournals.org/clincancerres/article-abstract/28/12/2480/699278/Sounding-the-Alarm-on-Leiomyosarcoma-Recurrence?redirectedFrom=fulltext" target="_blank" rel="noopener">Sounding the Alarm on Leiomyosarcoma Recurrence: Role of Circulating Tumor DNA</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/35727598/" target="_blank" rel="noopener">Cabozantinib + Temozolomide activity in uterine sarcoma</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/26727100/" target="_blank" rel="noopener">Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma</a></li>
                  <li>Uterine Sarcomas: How to Navigate an Ever‑Growing List of Subtypes — <a href="https://pubmed.ncbi.nlm.nih.gov/35471831/" target="_blank" rel="noopener">https://pubmed.ncbi.nlm.nih.gov/35471831/</a></li>
                  <li>Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review — <a href="https://pubmed.ncbi.nlm.nih.gov/35267488/" target="_blank" rel="noopener">PubMed</a> | <a href="https://www.mdpi.com/2072-6694/14/5/1180/html" target="_blank" rel="noopener">Full Text</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/35216305/" target="_blank" rel="noopener">Integrative Genomic and Transcriptomic Profiling: uLMS vs Leiomyoma</a></li>
                  <li><strong>Diagnostic and prognostic value of Bcl‑2 in uterine leiomyosarcoma</strong> — Systematic review & meta‑analysis</li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/35326717/" target="_blank" rel="noopener">Interrogating the Genomic Landscape of Uterine Leiomyosarcoma</a></li>
                  <li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759317/" target="_blank" rel="noopener">Soft Tissue and Uterine Leiomyosarcoma</a></li>
                  <li><a href="https://www.nature.com/articles/s41379-022-01011-z" target="_blank" rel="noopener">Morphology‑based risk stratification model (Stage I uLMS)</a></li>
                  <li><a href="https://www.cancer.columbia.edu/news/targeted-therapy-shows-promise-aggressive-form-uterine-sarcoma" target="_blank" rel="noopener">Targeted Therapy Shows Promise for Aggressive uLMS</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/35034043/" target="_blank" rel="noopener">HPV51‑associated Leiomyosarcoma: TP53/RB1‑Wildtype</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/33970096/" target="_blank" rel="noopener">Response of BRCA2/TP53/PTEN‑Deleted Metastatic uLMS to Olaparib</a></li>
                  <li><a href="https://www.eurekalert.org/news-releases/930384" target="_blank" rel="noopener">Epigenetic signatures differentiate uterine/soft tissue LMS</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/34532904/" target="_blank" rel="noopener">uLMS diagnosis after HIFU for fibroid — case</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/33595252/" target="_blank" rel="noopener">Uterine Morcellation for Presumed Leiomyomas — ACOG Opinion</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/34302054/" target="_blank" rel="noopener">BCORL1‑driven high‑grade endometrial stromal sarcomas</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/34284401/" target="_blank" rel="noopener">Reoperation with Total Hysterectomy after Incomplete Surgery</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/33158511/" target="_blank" rel="noopener">Impact of tumor fragmentation in stage I uLMS</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/34271247/" target="_blank" rel="noopener">IVC LMS: Surgical resection and graft replacement (multicenter)</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/34111973/" target="_blank" rel="noopener">Diagnostic interpretation of non‑contrast MR imaging features</a></li>
                  <li><a href="https://meetinglibrary.asco.org/record/198203/abstract" target="_blank" rel="noopener">ASCO 2021: uterine LMS molecularly distinct vs other sites</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/33964611/" target="_blank" rel="noopener">LMS of the urinary bladder — SEER comparison</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/33338329/" target="_blank" rel="noopener">Integrated histologic and molecular analysis of uLMS</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/33063261/" target="_blank" rel="noopener">Malignant Peritoneal Cytology significance in uterine sarcoma</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/33787622/" target="_blank" rel="noopener">Systemic treatment of uLMS: A systematic review</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/33922556/" target="_blank" rel="noopener">Resistance to Immune Checkpoint Blockade in uLMS</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/33876771/" target="_blank" rel="noopener">Integrated mutational landscape analysis of uLMS</a></li>
                  <li><a href="https://www.sciencedirect.com/science/article/pii/S2352578921000461" target="_blank" rel="noopener">Long‑Term Outcomes after CRS + HIPEC for Morcellated uLMS</a></li>
                  <li><a href="https://www.sciencedirect.com/science/article/pii/S2352578921000424" target="_blank" rel="noopener">Primary ovarian LMS — specialist unit experience</a></li>
                  <li><a href="https://www.sciencedirect.com/science/article/abs/pii/S0090825820340427" target="_blank" rel="noopener">Impact of tumor fragmentation in stage I uLMS — outcomes</a></li>
                  <li><a href="https://pubmed.ncbi.nlm.nih.gov/33419612/" target="_blank" rel="noopener">HIPEC for uterine LMS: Systematic review</a></li>
                  <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/32299819" target="_blank" rel="noopener">Genomic Landscape of Uterine Sarcomas — Prospective sequencing</a></li>
                  <li><a href="https://www.sciencedirect.com/science/article/pii/S0002937819309354" target="_blank" rel="noopener">Copper ions as therapeutic agents for uLMS</a></li>
                  <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/31200927" target="_blank" rel="noopener">Secondary surgical resection for recurrent uLMS</a></li>
                  <li><a href="https://linkinghub.elsevier.com/retrieve/pii/S030121151830993X" target="_blank" rel="noopener">Unexpected uterine sarcomas with power morcellation</a></li>
                  <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/31168260#" target="_blank" rel="noopener">Uterine Sarcomas — Tertiary Cancer Center experience (India)</a></li>
                </ul>

                <h3>Uterine LMS Treatment — from the American Cancer Society</h3>
                <h4>Leiomyosarcoma and undifferentiated sarcoma</h4>
                <p><strong>Stages I and II:</strong> Standard surgery is hysterectomy with BSO; lymph node evaluation as indicated. Adjuvant radiation may reduce local recurrence; chemo is considered in higher‑risk cases.</p>
                <p><strong>Stage III:</strong> Debulking/definitive surgery followed by radiation ± chemo depending on risk of recurrence.</p>
                <p><strong>Stage IV:</strong> IVA may be operable; otherwise radiation/chemo or both. IVB managed with systemic therapy; targeted therapy when appropriate.</p>
                <p>See ACS for details: Surgery, Radiation therapy, Chemotherapy, Targeted therapy.</p>
              </div>
            </div>
          </div>
        </div>
        <!-- END VERBATIM IMPORT -->
      </div>
    </details>
  </section>
</div>
